NCT02100852View on ClinicalTrials.gov

TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 12, 2014

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

TGR-1202 + Obinutuzumab + Chlorambucil

TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose

Trial Locations (2)

35805

TG Therapeutics Investigational Trial Site, Huntsville

38119

TG Therapeutics Investigational Trial Site, Memphis

All Listed Sponsors
lead

TG Therapeutics, Inc.

INDUSTRY

NCT02100852 - TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter